Prophylactic High-Dose rhEPO No Benefit for Preemies

This article originally appeared here.
Share this content:
Prophylactic High-Dose rhEPO No Benefit for Preemies
Prophylactic High-Dose rhEPO No Benefit for Preemies

WEDNESDAY, May 18, 2016 (HealthDay News) -- Prophylactic early high-dose recombinant human erythropoietin (rhEPO) given intravenously to very preterm infants does not improve neurodevelopmental outcomes at 2 years corrected age, according to a study published in the May 17 issue of the Journal of the American Medical Association.

Giancarlo Natalucci, M.D., from the University of Zurich, and colleagues randomized preterm infants born between 26 weeks 0 days and 31 weeks 6 days of gestation to receive rhEPO (228 infants) or placebo (220 infants) intravenously after birth. The authors assessed cognitive development with the Mental Development Index (MDI) at 2 years corrected age as the primary outcome.

The researchers found that at a mean age of 23.6 months, neurodevelopmental outcome data were available for 81 percent of infants. The mean MDI was not statistically significantly different between the rhEPO and placebo groups (93.5 versus 94.5; P = 0.56) The groups did not differ in terms of secondary outcomes.

"Among very preterm infants who received prophylactic early high-dose rhEPO for neuroprotection, compared with infants who received placebo, there were no statistically significant differences in neurodevelopmental outcomes at 2 years," the authors write. "Follow-up for cognitive and physical problems that may not become evident until later in life is required."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Potentially Unsafe Med Scripts Up for Dual Users With Dementia

Potentially Unsafe Med Scripts Up for Dual Users ...

Rates of PUM are higher among veterans with dementia using VA-Medicare Part D system

Menopausal Status Linked to Faster Lung Function Decline

Menopausal Status Linked to Faster Lung Function Decline

Transitional, postmenopausal women have increases in adjusted mean forced vital capacity decline

Social Media Rarely Used by Plastic Surgeons

Social Media Rarely Used by Plastic Surgeons

6 percent of posts about plastic surgery by plastic surgeons; 37 percent of these self-promotional

is free, fast, and customized just for you!

Already a member?

Sign In Now »